{"organizations": [], "uuid": "90421694bc7ab4c22bfc74f5dc658c07810359a5", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180116.html", "section_title": "Archive News &amp; Video for Tuesday, 16 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-rxi-pharmaceuticals-announces-busi/brief-rxi-pharmaceuticals-announces-business-strategy-to-focus-on-immuno-oncology-programs-to-accelerate-growth-idUSFWN1PB0LU", "country": "US", "domain_rank": 408, "title": "BRIEF-RXi Pharmaceuticals Announces Business Strategy To Focus On Immuno-Oncology Programs To Accelerate Growth", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.646, "site_type": "news", "published": "2018-01-16T20:35:00.000+02:00", "replies_count": 0, "uuid": "90421694bc7ab4c22bfc74f5dc658c07810359a5"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-rxi-pharmaceuticals-announces-busi/brief-rxi-pharmaceuticals-announces-business-strategy-to-focus-on-immuno-oncology-programs-to-accelerate-growth-idUSFWN1PB0LU", "ord_in_thread": 0, "title": "BRIEF-RXi Pharmaceuticals Announces Business Strategy To Focus On Immuno-Oncology Programs To Accelerate Growth", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "rxi pharmaceuticals", "sentiment": "negative"}, {"name": "rxi pharmaceuticals corp", "sentiment": "negative"}, {"name": "rxi", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 16 (Reuters) - Rxi Pharmaceuticals Corp:\n* RXI PHARMACEUTICALS ANNOUNCES BUSINESS STRATEGY TO FOCUS ON IMMUNO-ONCOLOGY PROGRAMS TO ACCELERATE GROWTH\n* RXI PHARMACEUTICALS CORP - COMPANY TO “CAPITALIZE” ON PROPRIETARY SELF-DELIVERING RNAI PLATFORM (SD-RXRNA)\n* RXI PHARMACEUTICALS CORP - 2018 BUSINESS STRATEGY INCLUDES DEVELOPING IMMUNO-ONCOLOGY TARGETS BEYOND CHECKPOINT INHIBITION, I.E. CELL DIFFERENTIATION\n* RXI PHARMACEUTICALS- RELATING TO OPERATIONAL REVIEW, RXI INTENDS TO PARTNER/OUT-LICENSE BOTH ITS DERMATOLOGY AND OPHTHALMOLOGY FRANCHISES Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-16T20:35:00.000+02:00", "crawled": "2018-01-17T19:48:46.000+02:00", "highlightTitle": ""}